| TITRE |
Étude de phase III: Radiothérapie par modulation d'intensité préopératoire VS post-opératoire pour les sarcomes des tissus mous du tronc et des extrémités. |
| PROTOCOLE ID |
RxTx 50/50 |
| CLINICAL TRIAL.gov ID |
n.d. |
| TYPE(S) DE CANCER |
Sarcome |
| PHASE |
Phase III |
| TYPE D'ÉTUDE |
Traitement |
| INSTITUTION |
CIUSSS DE L'EST-DE-L'ILE-DE-MONTREAL
5415 boul. de l'Assomption
(514) 252-3400
|
| VILLE |
Montréal
|
| INVESTIGATEUR(RICE) PRINCIPAL(E) |
Nader Khaouam
|
| COORDONATEUR(RICE) |
Jany Barry
jbarry.hmr@ssss.gouv.qc.ca
514-252-3400
|
| STATUT |
Fermé
|
| CRITÈRES D'ÉLIGIBILITÉ |
(EN)
- Histologically proven soft tissue sarcoma of the extremity or trunk following review by local reference pathologist.
- Deemed appropriate for preoperative or postoperative radiotherapy and conservative surgery following patient assessment by a radiation oncologist and surgical oncologist.
- Lesion is primary or locally recurrent. Patient may have undergone excisional biopsy with positive margins at a referring hospital and are eligible following discussion among the surgical oncologists and radiation oncologists that IMRT is an acceptable treatment for that case.
- ECOG 0-3
- Patient is aged 18 years or older.
- Patient is able to provide informed consent
- Patient is available for treatment and follow-up.
|
| CRITÈRES D'EXCLUSION |
(EN)
- Benign histology.
- Prior malignancy within the previous five years or concurrent malignancy with the exception of adequately treated basal cell carcinoma of the skin or carcinoma in-situ of the cervix.
- Prior radiotherapy to the target site
- Planned chemotherapy for (neo)adjuvant treatment
- Conservative surgery to the target site only
- Presence of regional nodal disease or unequivocal distant metastases.
- Other major medical illness deemed to preclude safe administration of protocol treatment or required follow-up.
|
